Renal diseases related to hematopoietic stem cell transplantation (HSCT) have been a serious problem. Imai et al
1
classified HSCT-related nephropathy into three groups according to the time of onset. Early-or middle-onset nephropathy included acute renal failure and hemolytic uremic syndrome/thrombotic thrombocytopenic purpura. Late-onset nephropathy (over 6 months after HSCT) included nephrotic syndrome (NS), which was predominant, and chronic renal failure. Recently, NS after HSCT has been reported in an association with graft-versus-host disease (GVHD). In most cases, NS shows a good response to immunosuppressive therapy without recurrence. Here, we report the first case of recurrent NS after peripheral blood stem cell transplantation (PBSCT).
A 52-year-old man had general fatigue and was given a diagnosis of Philadelphia-chromosome-positive chronic myeloid leukemia (CML) in August 2000. After interferon therapy did not result in remission, he underwent PBSCT from his HLA-identical sibling at the Department of Hematology in our hospital in May 2001. Conditioning therapy included total body irradiation of 12 Gy, cytarabine of 8 g/m 2 , and cyclophosphamide of 120 mg/kg. In addition, he received cyclosporine (CYA) at 150 mg/day and shortterm methotrexate therapy for the prophylaxis of GVHD. At 1 month after the PBSCT, CYA was withdrawn because of renal insufficiency. Thereafter, acute GVHD appeared as diarrhea, skin pigmentation, and mucosal ulceration. Prednisolone (PSL) at 30 mg/day was administered, and tapered to 10 mg/day after improvement of the symptoms.
The patient noticed edema in the lower extremities in September 2001. After 1 month, he was referred to our Department of Nephrology because of NS. Physical examination showed oral erosive mucositis, skin pigmentation, and pitting edema in the lower extremities. Serum total protein was 41 g/l. Urinary protein excretion was 3.5 g/day. Serum creatinine was 89.3 mmol/l. Hematologically, a recurrence of CML was not observed. Renal biopsy was performed, and light microscopy (LM) showed unremarkable glomerular and interstitial changes. Electron microscopy (EM) showed no electron-dense deposits. They were consistent with minimal-change disease (MCD). However, fine granular staining for IgG and C3 along the capillary walls was observed on immunofluorescence (IF) study. With the presumed diagnosis of MCD, PSL was increased to 20 mg/day and CYA at 100 mg/day was started. The patient was discharged in complete remission of NS in November 2001.
Thereafter, the patient was followed as a hematological outpatient. In March 2002, PSL was withdrawn and CYA was reduced to 50 mg/day because of suggestive signs of infection. After 1 month, NS recurred and did not improve despite treatment with PSL at 10 mg/day and CYA at 100 mg/day. At that time, he was again referred to our department.
On admission, physical examination showed pitting edema in the lower extremities. Hematological examination showed a white blood cell count of 7.5 Â 10 9 /l, hemoglobin of 125 g/l, and a platelet count of 129 Â 10 9 /l, without recurrence of CML. Serum total protein was 45 g/l. Serum creatinine was 92.8 mmol/l. Serologically, IgG, IgA, and IgM were 7.46, 0.54, and 1.21 g/l, respectively. Complements were within the normal range. Serological tests for hepatitis virus B and C were all negative. Urinary protein excretion was 4.5 g/day. In the second renal biopsy, LM showed unremarkable glomerular and interstitial change (Figure 1 ). However, histopathological discrepancy, fine granular staining for IgG and C3 along the capillary walls on IF (Figure 2 ) without electron-dense deposits on EM, was observed again. PSL was increased to 30 mg/day, together with CYA at 100 mg/day. The proteinuria disappeared 2 months later. Thereafter, the patient has been free from recurrence of NS or CML.
To our knowledge, glomerulopathy after HSCT has been reported in 22 cases in the English literature. The diagnosis was membranous nephropathy (MN) in 13 cases, MCD in five, crescentic glomerulonephritis in two, and focal segmental glomerulosclerosis (FSGS), and membranoproliferative glomerulonephritis in one each. Urinary protein excretion was 8.876.5 g/day (range 1-30). The interval from HSCT to proteinuria was 15.8710.5 months (range 4-48). The pathogenetic mechanism of glomerulopathy after HSCT still remains unclear. Preceding GVHD is considered a key event for its development. GVHD mimics the biological and clinical features of systemic lupus erythematosus or other immune complex (IC)-related disorders. In experimental models of GVHD, IC-related glomerular injury has been observed. 2 MN, the most predominant disease after HSCT in humans, is consistent with this observation. However, IC-related injury cannot be applied to other glomerulopathies, such as MCD or FSGS, in this setting. In these diseases, disordered cellular immunity has been suggested as the main pathogenesis. Circulating factors produced by activated T-cells are suggested to impair glomerular filtration barrier and lead to the development of glomerulopathies. The participation of disordered cellular immunity has been suggested also in MN 4 and crescentic glomerulonephritis 5, 6 in this setting by massive glomerular and interstitial infiltration of T-cells, monocytes or macrophages.
In the present case, the MN-like IF finding was confounding. It is very difficult to clarify the nature of the IF finding. It might be nonspecific staining or, although unusual, indicate early-stage MN. We made a diagnosis of MCD rather than MN, because of the absence of obvious electron-dense deposits on EM. In addition, NS after the withdrawal of CYA supports MCD and disordered cellular immunity. In GVHD, various cytokines released from donor T-cells play pathogenetic roles. 7 These cytokines could be candidates for glomerular permeability factors. In fact, one of the cytokines, tumor necrosis factor (TNF)-a, has increased the permeability of albumin in isolated glomeruli. 8 Cytokine production from activated T-cells could be inhibited by CYA. 3 Therefore, faster tapering or withdrawal of CYA might lead to insufficient immunosuppression and subsequent development of NS, as observed in at least eight of the 22 cases. There are no established predictors for the development or exacerbation of GVHD, but interferon-g or TNF-a may be possible candidates. 9 Various immunological disorders are involved in GVHD. GVHD-related glomerulopathy seems to be mainly mediated by IC. However, it is very likely that disordered cellular immunity may be involved in its development. 
